Exactis Innovation and SOPHiA GENETICS Announce Collaboration on Multimodal Data Analytics
Insights from multimodal datasets on the platform fuel cancer research in
Exactis Innovation is a non-profit network of hospital partners across
"Our enhanced focus on real-world data positions us as a key resource for impartial insights for both industry and public sectors. Our participation in contributing to, and learning from, the collective intelligence enabled by SOPHiA GENETICS stems from our belief that the path to superior data-driven decisions lies in overcoming borders and utilizing top-tier, ready-to-use real world data," said Kostas Trakas, PhD., CEO, Exactis Innovation.
"It is our continued goal to improve health outcomes for patients globally by equipping local health institutions with the technology needed to exercise data-driven medicine," said Jurgi Camblong, PhD., CEO and Co-founder of SOPHiA GENETICS. "As health data consumption grows and becomes increasingly complex and multifaceted, it is imperative that healthcare organizations have the ability to process data in a timely manner and receive highly accurate results. SOPHiA GENETICS and Exactis Innovation have the shared vision to improve cancer survivorship in
The collaboration will also enable Exactis to implement leading cancer testing solutions for its patient population, including MSK-ACCESS® and MSK-IMPACT® powered with SOPHiA DDM™ and HRD testing. The SOPHiA DDM™ Platform will support Exactis in its ability to increase the volume and speed of next-generation sequencing (NGS) testing and tumor profiling.
"From our modest beginnings in
Exactis leads
J.P. Morgan Healthcare Conference
Jurgi Camblong, PhD., CEO and Co-founder of SOPHiA GENETICS, will present at the 42nd annual J.P. Morgan Healthcare Conference on Thursday, January 11, 2024 at 9:00 a.m. PST. More details can be found at ir.sophiagenetics.com.
For more information on SOPHiA GENETICS, visit SOPHiAGENETICS.com or connect on X, LinkedIn, Facebook, and Instagram.
About SOPHiA GENETICS
SOPHiA GENETICS (Nasdaq: SOPH) is a software company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It is the creator of the SOPHiA DDM™ Platform, a cloud-native platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The SOPHiA DDM™ Platform and related solutions, products and services are currently used by a broad network of hospital, laboratory, and biopharma institutions globally. For more information, visit SOPHiAGENETICS.COM, or connect on X, LinkedIn, Facebook, and Instagram. Where others see data, we see answers.
SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures, unless specified otherwise. The information in this press release is about products that may or may not be available in different countries and, if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact support@sophiagenetics.com to obtain the appropriate product information for your country of residence.
SOPHiA GENETICS Forward-Looking Statements:
This press release contains statements that constitute forward-looking statements. All statements other than statements of historical facts contained in this press release, including statements regarding our future results of operations and financial position, business strategy, products, and technology, as well as plans and objectives of management for future operations, are forward-looking statements. Forward-looking statements are based on our management's beliefs and assumptions and on information currently available to our management. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various factors, including those described in our filings with the
View original content to download multimedia:https://www.prnewswire.com/news-releases/exactis-innovation-and-sophia-genetics-announce-collaboration-on-multimodal-data-analytics-302028250.html
SOURCE SOPHiA GENETICS